Marealis bioactive marine peptides from prawn shells improve blood pressure health

Hypertension is the leading cause of preventable death in the world. Today over half of the adult population in the western world are living with hypertension or pre-hypertension. While blood pressure can be managed for some through diet, exercise and stress reduction, the reality is that the majority are not able to manage their hypertension through lifestyle alone. As a result, many adults are prescribed routine medication which can cause side effects.

In the cold-water prawn industry, 60 per cent of the prawn is discarded as waste. In 2008 Stella Polaris, a leader in sustainable cold-water prawn production learned that Nofima, a leading research institution in Norway, had discovered that bioactive marine peptides derived from prawn shells could lower blood pressure. Marealis was founded to leverage this discovery.

Marealis has developed PreCardix – the world’s first bioactive marine peptides clinically proven to lower blood pressure. PreCardix contains some unique bioactive peptides derived from the proteins of fresh, cold-water Arctic prawn shells (Pandalus Borealis). This proprietary technology allowed PreCardix to leverage the prawn shell waste, and create a potent, natural blood pressure solution.

PreCardix is the result of over a decade of blood pressure research and clinical study dedicated to finding an effective, sustainable and proven natural blood pressure remedy.

Two clinical studies on PreCardix were conducted between 2012 and 2015 with over 220 male and female participants. Clinical results showed that the bioactive marine peptides unique to PreCardix have an ACE inhibiting effect on the body. This resulted in a significant blood pressure reduction in 89 per cent of participants within eight weeks or less. The proven blood pressure lowering effect of the all-natural PreCardix is comparable to common anti-hypertensive drugs. No side effects were documented during either study.

High blood pressure is the leading cause of heart disease and stroke, killing around 7.5 million people worldwide every year.

Marealis has received approvals from Health Canada, the US Federal Drug Administration (FDA) and the European Food Safety Authority (EFSA).

A certified B Corporation, Marealis is currently focused on the North American market where the company has been approved to use a unique blood pressure-specific health claim for PreCardix.

Marealis is also seeking business partners for commercialisation in other markets worldwide.